What Does the FDA Say About Digital Pathology for Nonclinical Toxicology Studies?

Let’s go through the “Use of Whole Slide Imaging in Nonclinical Toxicology Studies: Questions and Answers, Guidance for Industry” document together and see what is actually recommended when it comes to digital pathology for nonclinical tox studies.

Learning digital pathology can be a challenging journey, particularly with complex terminology and the rapid pace of change. But joining the Digital Pathology Club is your key to success. Imagine having a digital pathology expert at your side, guiding you every step of the way. You’ll gain access to a treasure trove of learning resources, a vibrant community of learners, and stay in the know with the latest advancements. When you join us, you’ll master digital pathology with ease, opening doors to exciting career opportunities. The stakes are high – if you join, you’ll thrive in this field; if you don’t, you might miss out on the chance of a lifetime. Act now, and let’s embark on this journey together.

• What the heck is DICOM in Pathology? w/ David Clunie, PixelMed Publishing
• What does the FDA say about non-clinical digital pathology for GLP?
• The Regulatory Aspect of Digital Pathology and Translational Medicine w/ Esther Abels
• Digital Pathology 101 Chapter 5 | The Role of Whole Slide Imaging in Toxicologic Pathology
• Welcome